English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Extended-spectrum beta-lactamase producing  Enterobacteriaceae  (ESBL-PE) infections are frequent and highly impact cancer patients. We developed and validated a scoring system to identify cancer patients harboring ESBL-PE at the National Institute of Cancer of Colombia.    Methods  We retrospectively analyzed medical records of 1695 cancer patients. Derivation phase included 710 patients admitted between 2013 to 2015, ESBL-PE positive culture ( n  = 265) paired by month and hospitalization ward with Non-ESBL-PE ( n  = 445). A crude and weighted score was developed by conditional logistic regression. The model was evaluated in a Validation cohort ( n  = 985) with the same eligibility criteria between 2016 to 2017.    Results  The score was based on eight variables (reported with Odds Ratio and 95% confidence interval): Hospitalization ≥7 days (5.39 [2.46–11.80]), Hospitalization during the previous year (4, 87 [2.99–7.93]), immunosuppressive therapy during the previous 3 months (2.97 [1.44–6.08]), Neutropenia (1.90 [1.12–3.24]), Exposure to Betalactams during previous month (1.61 [1.06–2.42]), Invasive devices (1.51 [1.012–2.25]), Neoplasia in remission (2.78 [1.25–1.17]), No chemotherapy during the previous 3 months (1.90 [1.22–2.97]). The model demonstrated an acceptable discriminatory capacity in the Derivation phase, but poor in the Validation phase (Recipient Operating Characteristic Curve: 0.68 and 0.55 respectively).    Conclusions  Cancer patients have a high prevalence of risk factors for ESBL-PE infection. The scoring system did not adequately discriminate patients with ESBL-PE. In a high-risk population, other strategies should be sought to identify patients at risk of resistant ESBL-PE infection.

bmc infectious diseases

Development and validation of a scoring system for predicting cancer patients at risk of extended-spectrum b-lactamase-producing Enterobacteriaceae infections